Your browser doesn't support javascript.
loading
The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells.
Paavola, Kevin J; Roda, Julie M; Lin, Vicky Y; Chen, Peirong; O'Hollaren, Kyle P; Ventura, Richard; Crawley, Suzanne C; Li, Betty; Chen, Hung-I H; Malmersjö, Seth; Sharkov, Nikolai A; Horner, Geoffrey; Guo, Wei; Kutach, Alan K; Mondal, Kalyani; Zhang, Zhen; Lichtman, Joshua S; Song, Christina; Rivera, Lee B; Liu, Wenhui; Luo, Jian; Wang, Yan; Solloway, Mark J; Allan, Bernard B; Kekatpure, Avantika; Starck, Shelley R; Haldankar, Raj; Fan, Bin; Chu, Chun; Tang, Jie; Molgora, Martina; Colonna, Marco; Kaplan, Daniel D; Hsu, Jer-Yuan.
Afiliação
  • Paavola KJ; NGM Biopharmaceuticals, South San Francisco, California.
  • Roda JM; NGM Biopharmaceuticals, South San Francisco, California.
  • Lin VY; NGM Biopharmaceuticals, South San Francisco, California.
  • Chen P; NGM Biopharmaceuticals, South San Francisco, California.
  • O'Hollaren KP; NGM Biopharmaceuticals, South San Francisco, California.
  • Ventura R; NGM Biopharmaceuticals, South San Francisco, California.
  • Crawley SC; NGM Biopharmaceuticals, South San Francisco, California.
  • Li B; NGM Biopharmaceuticals, South San Francisco, California.
  • Chen HH; NGM Biopharmaceuticals, South San Francisco, California.
  • Malmersjö S; NGM Biopharmaceuticals, South San Francisco, California.
  • Sharkov NA; NGM Biopharmaceuticals, South San Francisco, California.
  • Horner G; NGM Biopharmaceuticals, South San Francisco, California.
  • Guo W; NGM Biopharmaceuticals, South San Francisco, California.
  • Kutach AK; NGM Biopharmaceuticals, South San Francisco, California.
  • Mondal K; NGM Biopharmaceuticals, South San Francisco, California.
  • Zhang Z; NGM Biopharmaceuticals, South San Francisco, California.
  • Lichtman JS; NGM Biopharmaceuticals, South San Francisco, California.
  • Song C; NGM Biopharmaceuticals, South San Francisco, California.
  • Rivera LB; NGM Biopharmaceuticals, South San Francisco, California.
  • Liu W; NGM Biopharmaceuticals, South San Francisco, California.
  • Luo J; NGM Biopharmaceuticals, South San Francisco, California.
  • Wang Y; NGM Biopharmaceuticals, South San Francisco, California.
  • Solloway MJ; NGM Biopharmaceuticals, South San Francisco, California.
  • Allan BB; NGM Biopharmaceuticals, South San Francisco, California.
  • Kekatpure A; NGM Biopharmaceuticals, South San Francisco, California.
  • Starck SR; NGM Biopharmaceuticals, South San Francisco, California.
  • Haldankar R; NGM Biopharmaceuticals, South San Francisco, California.
  • Fan B; NGM Biopharmaceuticals, South San Francisco, California.
  • Chu C; NGM Biopharmaceuticals, South San Francisco, California.
  • Tang J; NGM Biopharmaceuticals, South San Francisco, California.
  • Molgora M; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
  • Colonna M; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
  • Kaplan DD; NGM Biopharmaceuticals, South San Francisco, California.
  • Hsu JY; NGM Biopharmaceuticals, South San Francisco, California. ahsu@ngmbio.com.
Cancer Immunol Res ; 9(11): 1283-1297, 2021 11.
Article em En | MEDLINE | ID: mdl-34426457
ABSTRACT
Suppressive myeloid cells inhibit antitumor immunity by preventing T-cell responses. Immunoglobulin-like transcript 3 (ILT3; also known as LILRB4) is highly expressed on tumor-associated myeloid cells and promotes their suppressive phenotype. However, the ligand that engages ILT3 within the tumor microenvironment and renders tumor-associated myeloid cells suppressive is unknown. Using a screening approach, we identified fibronectin as a functional ligand for ILT3. The interaction of fibronectin with ILT3 polarized myeloid cells toward a suppressive state, and these effects were reversed with an ILT3-specific antibody that blocked the interaction of ILT3 with fibronectin. Furthermore, ex vivo treatment of human tumor explants with anti-ILT3 reprogrammed tumor-associated myeloid cells toward a stimulatory phenotype. Thus, the ILT3-fibronectin interaction represents a "stromal checkpoint" through which the extracellular matrix actively suppresses myeloid cells. By blocking this interaction, tumor-associated myeloid cells may acquire a stimulatory phenotype, potentially resulting in increased antitumor T-cell responses.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Receptores Imunológicos / Fibronectinas / Células Mieloides Limite: Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Receptores Imunológicos / Fibronectinas / Células Mieloides Limite: Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2021 Tipo de documento: Article